<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02101411</url>
  </required_header>
  <id_info>
    <org_study_id>TCHIRB-1011207-E-F</org_study_id>
    <nct_id>NCT02101411</nct_id>
  </id_info>
  <brief_title>Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei City Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei City Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since thrombus formation is a very complex procedure in vivo, platelet function testing
      methods in vitro might only reflect the degree of inhibition of platelet from a certain
      level, which do't reflect the functional status of platelets in vivo adequately. There are a
      variety of signal transduction pathways involved in the formation of platelet activation and
      thrombosis. Gurbel et al. first reported individuals with variability on clopidogrel
      treatment response in 2003, and proposed the concept of clopidogrel resistance. Different
      patients received the same dose of aspirin or other anti -platelet drug such as clopidogrel ,
      due to various reasons bound to lack some patients antithrombotic efforts to increase the
      incidence of thrombotic events , while another part of the patient easily understood
      antithrombotic excessive bleeding events, &quot; antithrombotic individualized treatment , &quot;
      according to differences in patient against platelet drugs or anticoagulant drug reactions
      and adjust the treatment plan , is the direction of antithrombotic therapy in the future.

      There are a number of studies have shown that patients with no response Clopidogrel ,
      measuring the relationship between high platelet reactivity and clinical adverse ischemic
      events displayed between platelet activity . However, there is still lack of quantitative
      threshold high platelet reactivity and the risks associated with the clinical consensus . In
      addition, there are only limited data support, to measure platelet function -based therapy to
      improve the clinical efficacy of the concept . Over the years, more than 20,000 cases
      reported in patients with numerous studies confirm that high platelet reactivity after PCI
      with stent thrombosis , including cardiovascular events , including an increased risk of
      significant correlation . Pharmacodynamic analysis GRVITAS trial showed significantly lower
      platelet reactivity associated with a lower risk of adverse cardiovascular events . Brar in
      more than 3000 cases of patients published in JACC Meta-analysis showed that &quot;high platelet
      reactivity &quot; of patients whose cardiovascular death, heart attack and stent thrombosis
      occurred more than twice the rate of &quot; non-high platelet reactivity &quot; patients .

      Two new anti-platelet drugs (Prasugrel and Ticagrelor) in several recent randomized trials
      have considerable persuasive , and has included some guidance in the current guidelines.
      Ticagrelor even more than Prasugrel in pharmacodynamic studies more effectively inhibit
      platelet , and has a lower risk of bleeding. Cilostazol is an old drug , mostly for the
      treatment of intermittent claudication , in recent years there are also some testing and
      coronary stents prevent restenosis after angioplasty , however, so far , there is little
      direct comparison Cilostazol and Ticagrelor related articles .

      We designed this test , in addition to testing for high yellow people treat DAPT (dual
      anti-platelet therapy) under the platelet reactivity (high on-treatment platelet reactivity)
      ratio , this population of patients with ticagrelor instead for a month or cilostazol
      treatment after its platelet reactivity changes and compare between the two groups , and even
      track six months after the bleeding and adverse cardiovascular events rate? Through this test
      we can compare the treatment for patients with high platelet reactivity of what strategies
      more appropriate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">October 1, 2016</completion_date>
  <primary_completion_date type="Actual">May 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of Participants With MACE(Major Adverse Cardiac Event) of Study Subjects</measure>
    <time_frame>24 months</time_frame>
    <description>MACE(major adverse cardiac event) include: death, myocardial infarction, revascularization.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">334</enrollment>
  <condition>PRU(Platelet Reactivity Unit)</condition>
  <condition>APT(Antiplatelet Therapy)</condition>
  <condition>HOTPR(High on Treat Platelet Reactivity)</condition>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <description>treated with cloopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ticagrelor</arm_group_label>
    <description>treated with ticagrelor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cilostazol</arm_group_label>
    <description>treated with clopidogrel+cilostazol</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PRU(Platelet reactivity unit)</intervention_name>
    <description>measure by VeryfyNow.</description>
    <arm_group_label>cilostazol</arm_group_label>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_label>ticagrelor</arm_group_label>
    <other_name>Platelet reactivity unit</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        stable angina who received routine dual antiplatelet agents therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1 under DAPT (dual antiplatelet therapy) of stable angina patients for elective stent
        implantation.

        2. DAPT 24 hours, 7d and 30d after treatment PRU (platelet activity units) values. (Drug
        unresponsive patients was defined as PRU&gt; 235).

        Exclusion Criteria:

        1.Not suitable for the treatment of patients with DAPT. (Active peptic ulceration or
        bleeding) 2 patients of aspirin, clopidogrel, ticagrelor, cilostazol medication
        intolerance.

        3 contraindications for aspirin, clopidogrel, ticagrelor, cilostazol drug usage (such as
        heart failure patients not suitable for use cilostazol).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Yueh Chung, chief doctor</last_name>
    <role>Study Chair</role>
    <affiliation>taipei city hospital, taipei city goverment</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chen Yueh Chung, chief doctor</last_name>
    <role>Study Chair</role>
    <affiliation>taipei city hospital, tiapei city goverment</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei City Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>March 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2014</study_first_posted>
  <results_first_submitted>November 10, 2017</results_first_submitted>
  <results_first_submitted_qc>August 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2019</results_first_posted>
  <last_update_submitted>November 2, 2019</last_update_submitted>
  <last_update_submitted_qc>November 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei City Hospital</investigator_affiliation>
    <investigator_full_name>Yueh-Chung, Chen</investigator_full_name>
    <investigator_title>chief of ICU</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aspirin+Clopidogrel</title>
          <description>aspirin 100mg qd+clopidogrel 75mg qd</description>
        </group>
        <group group_id="P2">
          <title>Aspirin+Ticagrelor</title>
          <description>aspirin100mg qd+ticagrelor 90mg bid</description>
        </group>
        <group group_id="P3">
          <title>Aspirin+Clopidogrel+Cilostazol</title>
          <description>aspirin 100mg qd+clopidogrel 75mg qd+cilostazol 100mg bid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>PRU after anti-platelet drugs</population>
      <group_list>
        <group group_id="B1">
          <title>Aspirin+Clopidogrel</title>
          <description>aspirin 100mg qd+clopidogrel 75mg q...</description>
        </group>
        <group group_id="B2">
          <title>Aspirin+Ticagrelor</title>
          <description>aspirin100mg qd+ticagrelor 90mg bid</description>
        </group>
        <group group_id="B3">
          <title>Aspirin+Clopidogrel+Cilostazol</title>
          <description>aspirin 100mg qd+clopidogrel 75mg q...</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="107"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="104"/>
            <count group_id="B4" value="313"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" spread="13"/>
                    <measurement group_id="B2" value="66.1" spread="13.9"/>
                    <measurement group_id="B3" value="65.2" spread="13.4"/>
                    <measurement group_id="B4" value="65.8" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numbers of Participants With MACE(Major Adverse Cardiac Event) of Study Subjects</title>
        <description>MACE(major adverse cardiac event) include: death, myocardial infarction, revascularization.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin+Clopidogrel</title>
            <description>aspirin 100mg qd+clopidogrel 75mg qd</description>
          </group>
          <group group_id="O2">
            <title>Aspirin+Ticagrelor</title>
            <description>aspirin100mg qd+ticagrelor 90mg bid</description>
          </group>
          <group group_id="O3">
            <title>Aspirin+Clopidogrel+Cilostazol</title>
            <description>aspirin 100mg qd+clopidogrel 75mg qd+cilostazol 100mg bid</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Participants With MACE(Major Adverse Cardiac Event) of Study Subjects</title>
          <description>MACE(major adverse cardiac event) include: death, myocardial infarction, revascularization.</description>
          <units>numbers of participants with MACE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The differences among the three PRU groups (&lt;85, 85–208,&gt;208) and MACE rate at 24 months were compared using the Chi-squared test. was recorded.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The Chi-squared test was used for comparisons of all categorical variables. If 20% of the cells had an expected value &lt; 5, then Fisher’s exact test was used.</non_inferiority_desc>
            <p_value>0.002</p_value>
            <p_value_desc>The Chi-squared test was used for comparisons of all categorical variables. If 20% of the cells had an expected value &lt; 5, then Fisher’s exact test was used.</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>The differences among the three PRU groups (&lt;85, 85–208,&gt;208) and ADEs were compared using the Chi-squared test.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.19</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.005</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The differences among the three PRU groups (&lt;85, 85–208,&gt;208) and ADEs were compared using the Chi-squared test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The Chi-squared test was used for comparisons of all categorical variables. If 20% of the cells had an expected value &lt; 5, then Fisher’s exact test was used.</non_inferiority_desc>
            <p_value>0.002</p_value>
            <p_value_desc>The Chi-squared test was used for comparisons of all categorical variables. If 20% of the cells had an expected value &lt; 5, then Fisher’s exact test was used.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.005</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24m</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aspirin+Clopidogrel</title>
          <description>aspirin 100mg qd+clopidogrel 75mg qd</description>
        </group>
        <group group_id="E2">
          <title>Aspirin+Ticagrelor</title>
          <description>aspirin100mg qd+ticagrelor 90mg bid</description>
        </group>
        <group group_id="E3">
          <title>Aspirin+Clopidogrel+Cilostazol</title>
          <description>aspirin 100mg qd+clopidogrel 75mg qd+cilostazol 100mg bid</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>1</sub_title>
                <description>Myocardial infarction, or related death</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>chen yueh-chung</name_or_title>
      <organization>taipei city hospital</organization>
      <phone>88627093600 ext 3741</phone>
      <email>chenyuehchung.tw@yahoo.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

